Free Trial
NYSE:OSTX

OS Therapies (OSTX) Stock Price, News & Analysis

OS Therapies logo
$1.56 +0.01 (+0.97%)
As of 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About OS Therapies Stock (NYSE:OSTX)

Key Stats

Today's Range
$1.36
$1.61
50-Day Range
$1.12
$1.97
52-Week Range
$1.12
$7.00
Volume
82,822 shs
Average Volume
484,699 shs
Market Capitalization
$34.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

OS Therapies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

OSTX MarketRank™: 

OS Therapies scored higher than 45% of companies evaluated by MarketBeat, and ranked 628th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OS Therapies has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    OS Therapies has only been the subject of 2 research reports in the past 90 days.

  • Read more about OS Therapies' stock forecast and price target.
  • Earnings Growth

    Earnings for OS Therapies are expected to grow in the coming year, from ($0.64) to ($0.22) per share.

  • Short Interest

    There is no current short interest data available for OSTX.
  • Dividend Yield

    OS Therapies does not currently pay a dividend.

  • Dividend Growth

    OS Therapies does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for OSTX.
  • News Sentiment

    OS Therapies has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for OS Therapies this week, compared to 2 articles on an average week.
  • Search Interest

    Only 7 people have searched for OSTX on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added OS Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OS Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $351,516.00 in company stock.

  • Percentage Held by Insiders

    13.80% of the stock of OS Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about OS Therapies' insider trading history.
Receive OSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OS Therapies and its competitors with MarketBeat's FREE daily newsletter.

OSTX Stock News Headlines

OS Therapies granted FDA meeting for OST-HER2
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
OS Therapies FDA Meeting Request Granted
See More Headlines

OSTX Stock Analysis - Frequently Asked Questions

OS Therapies' stock was trading at $4.28 at the start of the year. Since then, OSTX shares have decreased by 62.9% and is now trading at $1.59.
View the best growth stocks for 2025 here
.

OS Therapies (OSTX) raised $8 million in an IPO on Thursday, August 1st 2024. The company issued 2,000,000 shares at $4.00 per share. Brookline Capital Markets (Division of Arcadia Securities LLC) served as the underwriter for the IPO.

Shares of OSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OS Therapies investors own include AST SpaceMobile (ASTS), Energy Transfer (ET), Black Stone Minerals (BSM), Kinder Morgan (KMI), Main Street Capital (MAIN), Atlas Energy Solutions (AESI) and Chevron (CVX).

Company Calendar

Today
4/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:OSTX
Previous Symbol
NYSE:OSTX
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$20.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+1,032.1%
Consensus Rating
Buy
Rating Score (0-4)
3.40
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$34.45 million
Optionable
N/A
Beta
N/A
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NYSE:OSTX) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners